Table 1.
Baseline demographics and tumor characteristics of HCC patients.
| Total (n = 87) | Tandem size | P-valuea | Doxorubicin loading | P-valuea | ||||
|---|---|---|---|---|---|---|---|---|
| 75 μm (n = 26) | 100 μm (n = 61) | Half-loaded (n = 15) | Full-loaded (n = 72) | |||||
| Clinical characteristics | ||||||||
| Age (years)b | 67.2 ± 10.6 | 67.2 ± 9.4 | 67.2 ± 11.1 | 0.993 | 71.9 ± 8.0 | 66.3 ± 10.8 | 0.056 | |
| Gender | 0.249 | 0.502 | ||||||
| Male | 69 (79.3%) | 23 (88.5%) | 46 (75.4%) | 11 (73.3%) | 58 (80.6%) | |||
| Female | 18 (20.7%) | 3 (11.5%) | 15 (24.6%) | 4 (26.7%) | 14 (19.4%) | |||
| Family medical history | 0.078 | 1.000 | ||||||
| No | 83 (95.4%) | 23 (88.5%) | 60 (98.4%) | 15 (100%) | 68 (94.4%) | |||
| Yes | 4 (4.6%) | 3 (11.5%) | 1 (1.6%) | 0 (0%) | 4 (5.6%) | |||
| HBV | 0.244 | 1.000 | ||||||
| No | 46 (52.9%) | 11 (42.3%) | 35 (57.4%) | 8 (53.3%) | 38 (52.8%) | |||
| Yes | 41 (47.1%) | 15 (57.7%) | 26 (42.6%) | 7 (46.7%) | 34 (47.2%) | |||
| HCV | 0.801 | 0.537 | ||||||
| No | 61 (70.1%) | 19 (73.1%) | 42 (68.9%) | 12 (80.0%) | 49 (68.1%) | |||
| Yes | 26 (29.9%) | 7 (26.9%) | 19 (31.2%) | 3 (20.0%) | 23 (31.9%) | |||
| Medication for HBV or HCV | 0.606 | 0.539 | ||||||
| No | 62 (71.3%) | 20 (76.9%) | 42 (68.8%) | 12 (80.0%) | 50 (69.4%) | |||
| Yes | 25 (28.7%) | 6 (23.1%) | 19 (31.2%) | 3 (20.0%) | 22 (30.6%) | |||
| Fatty liver disease | 1.000 | 0.717 | ||||||
| No | 72 (82.8%) | 22 (84.6%) | 50 (82.0%) | 12 (80.0%) | 60 (83.3%) | |||
| Yes | 15 (17.2%) | 4 (15.4%) | 11 (18.0%) | 3 (20.0%) | 12 (16.7%) | |||
| Alcoholic liver disease | 0.719 | 0.650 | ||||||
| No | 78 (89.7%) | 24 (92.3%) | 54 (88.5%) | 13 (86.7%) | 65 (90.3%) | |||
| Yes | 9 (10.3%) | 2 (7.7%) | 7 (11.5%) | 2 (13.3%) | 7 (9.7%) | |||
| Tumor burden | ||||||||
| Tumor sizec | 4.5 (2.5, 7.2) | 4.4 (2.1, 8.6) | 4.7 (2.6, 7.2) | 0.817 | 3.5 (2.2, 6.6) | 5 (2.7, 7.5) | 0.212 | |
| Child–Pugh scorec | 5 (5, 6) | 5 (5, 6) | 5 (5, 6) | 0.231 | 6 (5, 7) | 5 (5, 6) | 0.010 | |
| ECOG | 1.000 | 1.000 | ||||||
| 0 | 84 (96.6%) | 25 (96.2%) | 59 (96.7%) | 15 (100%) | 69 (95.8%) | |||
| 1 | 3 (3.5%) | 1 (3.8%) | 2 (3.3%) | 0 (0%) | 3 (4.2%) | |||
| CLIP stage | 0.065 | 0.499 | ||||||
| 0 | 13 (14.9%) | 7 (26.9%) | 6 (9.8%) | 3 (20.0%) | 10 (13.9%) | |||
| 1 | 46 (52.9%) | 14 (53.9%) | 32 (52.5%) | 9 (60.0%) | 37 (51.4%) | |||
| ≥ 2 | 28 (32.2%) | 5 (19.2%) | 23 (37.7%) | 3 (20.0%) | 25 (34.7%) | |||
| BCLC classification | 0.611 | 0.365 | ||||||
| A | 26 (29.9%) | 9 (34.6%) | 17 (27.9%) | 6 (40.0%) | 20 (27.8%) | |||
| B + C + D | 61 (70.1%) | 17 (65.4%) | 44 (72.1%) | 9 (60.0%) | 52 (72.2%) | |||
| Infiltrative HCC | 1.000 | 1.000 | ||||||
| No | 80 (91.95%) | 24 (92.3%) | 56 (91.8%) | 14 (93.3%) | 66 (91.7%) | |||
| Yes | 7 (8.05%) | 2 (7.7%) | 5 (8.2%) | 1 (6.7%) | 6 (8.3%) | |||
| Doxorubicin dosage (mg) | 47.5 ± 23.7 | 48.7 ± 16.9 | 46.9 ± 26.2 | 0.144 | 46.6 ± 27.5 | 47.6 ± 23.1 | 0.657 | |
aMann-Whitney test was used for continuous variables and Fisher’s exact test was used for categorical variables.
bMean ± standard deviation was presented.
cMedian (inter-quartile range) was presented.
Dox doxorubicin, HBV hepatitis B virus, HCV hepatitis C virus, ECOG Eastern Cooperative Oncology Group, CLIP cancer of the liver Italian program, BCLC Barcelona Clinic Liver Cancer, HCC hepatocellular carcinoma.